The company has already received tentative FDA approval within 30 months of filing, positioning the product for a shared 180-day exclusivity period upon launch. Shares of Zydus Lifesciences Ltd ended at ₹1,013.25, up by ₹5.05, or 0.50%, on the BSE.
The company has already received tentative FDA approval within 30 months of filing, positioning the product for a shared 180-day exclusivity period upon launch. Shares of Zydus Lifesciences Ltd ended at ₹1,013.25, up by ₹5.05, or 0.50%, on the BSE.